ZEB2

Across TCGA pan-cancer cohorts, ZEB2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated ZEB2 data layer compared with 10 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZEB2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated ZEB2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and MESO are the cancer types where ZEB2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.595	0.329	.001	59	view →
HNSC	DFS	Tertile	IV	0.496	0.243	.001	50	view →
MESO	OS	Tertile	All	0.272	0.507	.005	46	view →
UCS	DFS	Quartile	II,III,IV	0.637	0.160	.006	34	view →
KIRC	DFS	Median	All	0.732	0.517	<.001	31	view →
ACC	DFS	Median	All	0.305	0.592	.002	28	view →
LUSC	DFS	Median	All	0.298	0.459	.007	25	view →
CHOL	DFS	Tertile	All	0.743	0.188	.006	18	view →
SARC	OS	Median	All	0.830	0.622	.001	13	view →
SCLC	DFS	Tertile	IV	0.137	0.534	.024	12	view →
THCA	OS	Tertile	III,IV	0.919	0.998	.020	11	view →
STAD	DFS	Quartile	All	0.554	0.790	.022	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

ZEB2–LUAD (OS)

Open the LUAD breakdown →